

Table SI. Demographic data of patients in the study

Skin toxicities	Patients n (%)	Age, years Min–Max (Mean)	Female n (%)	Male n (%)	Skin type			Treatment		Follow-up ^b , days Range (mean)
					I–II n (%)	III–IV n (%)	Single n (%)	Combined ^d n (%)		
Total	59 (100)	31–80 (55.3)	19 (32.2)	40 (67.8)	43 (72.9)	16 (27.1)	47 (80)	12 (20)	25–758 (204.2)	
At least 1 ST	53 (89.8)	31–80 (55.58)	18 (94.7)	35 (87.5)	38 (88.3)	15 (93.7)	42 (89.3)	11 (91.6)	2–698 (159.32)	
NMSC (all included)	23 (39)	32–80 (59.35)	7 (36.8)	16 (40)	17 (39.5)	6 (37.5)	20 (42.5)	3 (25)	10–358 (77.7)	
SCC	4 (6.8)	58–80 (70.7)	1 (5.2)	3 (7.5)	3 (6.9)	1 (6.25)	4 (8.5)	–	35–112 (78.5)	
KA	12 (20.3)	38–80 (63)	3 (15.7)	9 (22.5)	3 (6.9)	2 (12.5)	11 (23.4)	1 (8.3)	16–127 (65.17)	
AK	16 (27.1)	32–80 (60.19)	6 (31.5)	10 (25)	10 (23.2)	6 (37.5)	14 (29.7)	2 (16.6)	10–358 (78.69)	
SK	36 (61)	31–80 (59.31)	12 (63.1)	24 (60)	24 (55.8)	12 (75)	31 (66)	5 (41.7)	15–364 (73.31)	
PPK	20 (33.9)	35–77 (54.47)	6 (31.5)	14 (35)	15 (34.8)	5 (31.2)	16 (34)	4 (33.3)	2–358 (127.14)	
Verrucous papilloma	28 (47.5)	32–80 (57.61)	10 (52.6)	18 (45)	20 (46.5)	8 (50)	26 (55.3)	2 (16.7)	15–378 (112.26)	
Keratosis pilaris	19 (32.2)	31–78 (49.4)	6 (31.5)	13 (32.5)	15 (34.8)	4 (25)	15 (31.9)	4 (33.3)	27–403 (121)	
Acneiform eruption/folliculitis	18 (30.5)	32–74 (51.67)	2 (10.5)	16 (40)	15 (34.8)	3 (18.7)	13 (27.7)	5 (41.7)	16–602 (295.6)	
Comedone	4 (6.8)	45–68 (51.5)	–	4 (10)	4 (9.3)	–	3 (6.3)	1 (8.3)	112–602 (234.2)	
Epidermal cyst	4 (6.8)	32–68 (51.5)	2 (10.5)	2 (5)	3 (6.9)	1 (6.2)	3 (6.3)	1 (8.3)	28–498 (263.75)	
Milium	6 (10.2)	38–68 (58.83)	2 (10.5)	4 (10)	5 (11.6)	1 (6.2)	5 (10.6)	1 (8.3)	14–299 (85.5)	
Hair loss	15 (25.4)	32–77 (55.47)	4 (21)	11 (27.5)	11 (25.5)	4 (25)	11 (23.4)	4 (33.3)	10–448 (154.13)	
Curly hair	6 (10.2)	37–77 (65.83)	2 (10.5)	4 (10)	3 (6.9)	3 (18.7)	2 (4.2)	4 (33.3)	10–448 (235.17)	
Photosensitivity	26 (44.1)	31–77 (57.58)	8 (42.1)	18 (45)	17 (39.5)	9 (56.25)	20 (42.6)	6 (50)	2–403 (97.42)	
Rash	10 (16.9)	35–77 (57.6)	4 (21)	6 (15)	7 (16.2)	3 (18.75)	8 (17)	2 (16.7)	4–147 (56.7)	
Conjunctival erythema	6 (10.2)	32–76 (58.67)	3 (15.7)	3 (7.5)	4 (9.3)	2 (12.5)	5 (10.6)	1 (8.3)	10–91 (45.17)	
Xerosis	21 (35.5)	31–71 (52.76)	8 (42.1)	13 (32.5)	16 (37.2)	5 (31.25)	17 (36.2)	4 (33.3)	10–358 (96.68)	
PPD	4 (6.8)	42–74 (60.75)	1 (5.2)	3 (7.5)	2 (4.6)	2 (12.5)	3 (6.3)	1 (8.3)	96–698 (236.2)	
Granulomatous dermatitis	1 (1.7)	46	–	1 (2.5)	1 (2.3)	–	1 (2.1)	–	113	
Vitiligo	5 (8.5)	36–73 (55.4)	–	5 (12.5)	3 (6.9)	2 (12.5)	4 (8.5)	1 (8.3)	112–698 (354.6)	

^aCombined treatment with dabrafenib, 400 mg/day, and trametinib, 2 mg/day. ^bThis column details the total follow-up range and mean time and the range and mean time of appearance for each ST.

ST: skin toxicity; NMSC: non-melanoma skin cancer; SCC: squamous cell carcinoma; KA: keratoacanthoma; AK: actinic keratosis; SK: seborrheic keratosis; PPK: palmoplantar keratoderma; PPD: palmoplantar dysesthesia.